---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-009383"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:29:58.481613+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ChromaDex posts Q4 net income of $0.1M; FY2023 revenue up 16% to $83.6M

## Summary
- Q4 net sales $21.2M (+1% YoY); Tru Niagen sales $17.6M (+9% YoY).
- Q4 gross margin 61.0% (up 380 bps); net income $0.1M vs loss of $1.4M prior year.
- Full-year net loss improved $11.6M to $4.9M; positive Adjusted EBITDA of $1.9M.
- Cash $27.3M, no debt; positive operating cash flow for fourth consecutive quarter.
- Exceeded FY2023 outlook for gross margin and G&A; expects accelerated growth in 2024.

## SEC filing metadata
- accession: 0001628280-24-009383
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/0001628280-24-009383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/cdxc-20240306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-009383
- JSON: https://secwatch.observer/filing/0001628280-24-009383.json
- Plain text: https://secwatch.observer/filing/0001628280-24-009383.txt

## Key facts
- Earnings Releases
  Niagen Bioscience, Inc. reported Fourth Quarter 2023 results: revenue $21.2 million, net income net income of $0.1 million, EPS $0.00 earnings per share.
  - Period: Fourth Quarter 2023
  - Revenue: $21.2 million
  - Net income: net income of $0.1 million
  - EPS: $0.00 earnings per share
  - Result: reported results
  source text: Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/0001628280-24-009383-index.htm
- Earnings Releases
  Niagen Bioscience, Inc. reported Fiscal Year 2023 results: revenue $83.6 million, net income net loss of only $4.9 million, EPS $0.07 loss per share.
  - Period: Fiscal Year 2023
  - Revenue: $83.6 million
  - Net income: net loss of only $4.9 million
  - EPS: $0.07 loss per share
  - Result: reported results
  source text: Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/0001628280-24-009383-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.